Nurix Therapeutics Q2 Revenue Surges to $44.1M, Exceeding Expectations

Nurix Therapeutics (NRIX) reported a significant increase in Q2 revenue to $44.1 million, exceeding the expected $17.51 million. The boost was driven by $30 million in license revenue from two extended partnerships with Sanofi and a $5 million milestone from its collaboration with Gilead. The company also witnessed pivotal developments, including Sanofi extending its license for Nurix's STAT6 program and the FDA's clearance of the investigational new drug application for the IRAK4 degrader GS-6791/NX-0479.

July 2, 2025

Nurix Therapeutics (NRIX) announced robust financial results for the second quarter of 2025, with revenue surging to $44.1 million, a significant increase from the previous year’s $12.1 million. The company attributed this growth to substantial license revenue and clinical milestone achievements, underlining its strategic partnerships and clinical advancements.

The primary driver of the revenue increase was $30 million in license revenue from two extended partnerships with Sanofi and a $5 million milestone from its collaboration with Gilead [1]. Sanofi extended its license for Nurix’s STAT6 program, including the STAT6 degrader development candidate NX-3911, which triggered a $15 million payment, bringing the total received by Nurix under this collaboration to $127 million [1]. Additionally, the FDA’s clearance of the investigational new drug (IND) application for the IRAK4 degrader GS-6791/NX-0479 paved the way for Gilead to initiate Phase 1 trials [1].

Key clinical highlights included the presentation of updated data for bexobrutideg (NX-5948) at the 30th European Hematology Association Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML-18), showcasing a robust objective response rate (ORR) of 80.9% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM) [1]. These results support the advancement of bexobrutideg to pivotal studies in CLL and underscore its potential to address significant unmet needs in B-cell malignancies.

The company also reported a net loss of $43.5 million for the quarter, driven by increased research and development expenses, primarily related to clinical, contract manufacturing, and consulting costs, as well as a rise in general and administrative expenses [1]. Despite the loss, Nurix’s strong financial position was bolstered by $485.8 million in cash, cash equivalents, and marketable securities as of May 31, 2025 [1].

Looking ahead, Nurix anticipates providing additional clinical updates for bexobrutideg and initiating pivotal trials in CLL in the second half of 2025. The company is also exploring the filing of a non-malignant hematology IND for autoimmune cytopenias in 2025 [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9491842/nurix-therapeutics-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update